Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443809 in Healthy Adults
NCT06326814Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR443809 in paroxysmal nocturnal hemoglobinuria (PNH) (7 arms), sponsored by Sanofi. Primary endpoints: Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs) and Incidence of potentially Clinical laboratory abnormalities. Started Oct 2021; status: completed.
02
Drugs
SAR443809
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06326814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326814.